Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement.

Abu-Baker A, Kharma N, Perreault J, Grant A, Shekarabi M, Maios C, Dona M, Neri C, Dion PA, Parker A, Varin L, Rouleau GA.

Mol Ther Nucleic Acids. 2019 Apr 15;15:12-25. doi: 10.1016/j.omtn.2019.02.003. Epub 2019 Feb 15.

2.

Valproic acid is protective in cellular and worm models of oculopharyngeal muscular dystrophy.

Abu-Baker A, Parker A, Ramalingam S, Laganiere J, Brais B, Neri C, Dion P, Rouleau G.

Neurology. 2018 Aug 7;91(6):e551-e561. doi: 10.1212/WNL.0000000000005942. Epub 2018 Jul 13.

3.

Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript.

Kharma N, Varin L, Abu-Baker A, Ouellet J, Najeh S, Ehdaeivand MR, Belmonte G, Ambri A, Rouleau G, Perreault J.

Nucleic Acids Res. 2016 Feb 29;44(4):e39. doi: 10.1093/nar/gkv1111. Epub 2015 Nov 2.

4.

Congenital massive hiatus hernia type IV; initial experience with laparoscopic repair in young infant.

Bataineh ZA, Rousan LA, Abu Baker A, Wahdow H, Kiwan RN, Saleem MM.

Hernia. 2014 Jun;18(3):427-9. doi: 10.1007/s10029-014-1222-z. Epub 2014 Feb 5.

PMID:
24497129
5.

Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/β-catenin pathway.

Abu-Baker A, Laganiere J, Gaudet R, Rochefort D, Brais B, Neri C, Dion PA, Rouleau GA.

Cell Death Dis. 2013 Oct 3;4:e821. doi: 10.1038/cddis.2013.342.

6.

A continuous professional development process for first-year pharmacy students.

O'Brocta R, Abu-Baker A, Budukh P, Gandhi M, Lavigne J, Birnie C.

Am J Pharm Educ. 2012 Mar 12;76(2):29. doi: 10.5688/ajpe76229.

7.

Development and evaluation of a required patient safety course.

Sukkari SR, Sasich LD, Tuttle DA, Abu-Baker AM, Howell H.

Am J Pharm Educ. 2008 Jun 15;72(3):65.

8.

Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1.

Catoire H, Pasco MY, Abu-Baker A, Holbert S, Tourette C, Brais B, Rouleau GA, Parker JA, Néri C.

Hum Mol Genet. 2008 Jul 15;17(14):2108-17. doi: 10.1093/hmg/ddn109. Epub 2008 Apr 7.

PMID:
18397876
9.

Teriparatide in the treatment of osteoporosis.

Stroup J, Kane MP, Abu-Baker AM.

Am J Health Syst Pharm. 2008 Mar 15;65(6):532-9. doi: 10.2146/ajhp070171. Review.

PMID:
18319498
10.

The utility of oral diabetes medications in type 2 diabetes of the young.

Kane MP, Abu-Baker A, Busch RS.

Curr Diabetes Rev. 2005 Feb;1(1):83-92. Review.

PMID:
18220585
11.

Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.

Stroup JS, Rivers SM, Abu-Baker AM, Kane MP.

Pharmacotherapy. 2007 Jun;27(6):779-88.

PMID:
17542760
12.

Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy.

Messaed C, Dion PA, Abu-Baker A, Rochefort D, Laganiere J, Brais B, Rouleau GA.

Neurobiol Dis. 2007 Jun;26(3):546-57. Epub 2007 Feb 15.

PMID:
17418585
13.

Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.

Abu-Baker A, Rouleau GA.

Biochim Biophys Acta. 2007 Feb;1772(2):173-85. Epub 2006 Oct 11. Review.

14.
15.

Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy.

Abu-Baker A, Messaed C, Laganiere J, Gaspar C, Brais B, Rouleau GA.

Hum Mol Genet. 2003 Oct 15;12(20):2609-23. Epub 2003 Aug 27.

PMID:
12944420
16.

The camel jockey's tibial fracture.

Sankaran-Kutty M, Abu Baker A.

Injury. 1994 Apr;25(3):155-7.

PMID:
8168885
17.

Physical and sensory attributes of hot-processed and conventionally chilled hams and bellies from electrically stimulated and non-stimulated pork carcasses.

Wiley EL, Reagan JO, Abu-Baker A, Carpenter JA, Reynolds AE, Miller MF.

Meat Sci. 1988;24(2):133-41. doi: 10.1016/0309-1740(88)90054-X.

PMID:
22055886

Supplemental Content

Loading ...
Support Center